Trials / Unknown
UnknownNCT06126237
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase I/II, Multiple Center, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM313 injection | CM313, subcutaneous injection |
Timeline
- Start date
- 2024-02-28
- Primary completion
- 2026-02-28
- Completion
- 2026-02-28
- First posted
- 2023-11-13
- Last updated
- 2023-11-13
Source: ClinicalTrials.gov record NCT06126237. Inclusion in this directory is not an endorsement.